Indication

IDH2-mutant Glioma

1 clinical trial

1 product

1 drug

Clinical trial

A Phase 1b/2, Multicenter Study of Vorasidenib in Combination With Temozolomide (TMZ) in Participants With IDH1- or IDH2-mutant Glioma

Status: Not yet recruiting, Estimated PCD: 2028-01-01

Drug

Product